{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:21:27Z","timestamp":1793125287622,"version":"4.5.0"},"reference-count":194,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Therapeutic drug monitoring (TDM) receives growing interest in different psychiatric clinical settings (emergency, inpatient, and outpatient services). Despite its usefulness, TDM remains underemployed in mental health. This is partly due to the need for evidence about the relationship between drug serum concentration and efficacy and tolerability, both in the general population and even more in subpopulations with atypical pharmacokinetics. This work aims at reviewing the scientific literature published after 2017, when the most recent guidelines about the use of TDM in mental health were written. We found 164 pertinent records that we included in the review. Some promising studies highlighted the possibility of correlating early drug serum concentration and clinical efficacy and safety, especially for antipsychotics, potentially enabling clinicians to make decisions on early laboratory findings and not proceeding by trial and error. About populations with pharmacokinetic peculiarities, the latest studies confirmed very common alterations in drug blood levels in pregnant women, generally with a progressive decrease over pregnancy and a very relevant dose-adjusted concentration increase in the elderly. For adolescents also, several drugs result in having different dose-related concentration values compared to adults. These findings stress the recommendation to use TDM in these populations to ensure a safe and effective treatment. Moreover, the integration of TDM with pharmacogenetic analyses may allow clinicians to adopt precise treatments, addressing therapy on an individual pharmacometabolic basis. Mini-invasive TDM procedures that may be easily performed at home or in a point-of-care are very promising and may represent a turning point toward an extensive real-world TDM application. Although the highlighted recent evidence, research efforts have to be carried on: further studies, especially prospective and fixed-dose, are needed to replicate present findings and provide clearer knowledge on relationships between dose, serum concentration, and efficacy\/safety.<\/jats:p>","DOI":"10.3390\/pharmaceutics14122674","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T02:24:46Z","timestamp":1669861486000},"page":"2674","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Filippo","family":"Pennazio","sequence":"first","affiliation":[{"name":"Department of Neuroscience \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9363-2506","authenticated-orcid":false,"given":"Claudio","family":"Brasso","sequence":"additional","affiliation":[{"name":"Department of Neuroscience \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Villari","sequence":"additional","affiliation":[{"name":"Psychiatric Emergency Service, Department of Neuroscience and Mental Health, A.O.U. \u201cCitt\u00e0 della Salute e della Scienza di Torino\u201d, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Neuroscience \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00228-007-0430-1","article-title":"Clinical Utility of Drug Measurement and Pharmacokinetics: Therapeutic Drug Monitoring in Psychiatry","volume":"64","author":"Hiemke","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00406-017-0798-6","article-title":"Guideline Adherence of Antidepressant Treatment in Outpatients with Major Depressive Disorder: A Naturalistic Study","volume":"267","author":"Herzog","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0031-1286281","article-title":"Therapeutic Drug Monitoring in Italian Psychiatry","volume":"44","author":"Conca","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/FTD.0b013e318296a2ff","article-title":"Therapeutic Drug Monitoring of Psychotropic Drugs in China: A Nationwide Survey","volume":"35","author":"Guo","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/pcn.13147","article-title":"Inadequate Therapeutic Drug Monitoring in Patients with Lithium Toxicity in Japan","volume":"74","author":"Okada","year":"2020","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1177\/1039856219866361","article-title":"Therapeutic Drug Monitoring (TDM) during Maintenance Phase Treatment at a Community Mental Health Centre","volume":"27","author":"Meehan","year":"2019","journal-title":"Australas. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40345-018-0120-1","article-title":"Monitoring of Patients Treated with Lithium for Bipolar Disorder: An International Survey","volume":"6","author":"Nederlof","year":"2018","journal-title":"Int. J. Bipolar Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/FTD.0000000000000483","article-title":"Prevalence of Therapeutic Drug Monitoring for Lithium and the Impact of Regulatory Warnings: Analysis Using Japanese Claims Database","volume":"40","author":"Ooba","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_10","first-page":"e7612","article-title":"Therapeutic Drug Monitoring Characteristics in a Tertiary University Hospital in 2019","volume":"12","author":"Ozunal","year":"2020","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FTD.0000000000000830","article-title":"Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs","volume":"43","author":"Schoretsanitis","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Toja-Camba, F.J., Gesto-Antelo, N., Maro\u00f1as, O., Echarri Arrieta, E., Zarra-Ferro, I., Gonz\u00e1lez-Barcia, M., Band\u00edn-Vilar, E., Mangas Sanjuan, V., Facal, F., and Arrojo Romero, M. (2021). Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13070935"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/15622975.2021.1878427","article-title":"Tools for Optimising Pharmacotherapy in Psychiatry (Therapeutic Drug Monitoring, Molecular Brain Imaging and Pharmacogenetic Tests): Focus on Antidepressants","volume":"22","author":"Eap","year":"2021","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/0929867324666170712165042","article-title":"New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs","volume":"25","author":"Mandrioli","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/med.21671","article-title":"New-Generation, Non-SSRI Antidepressants: Drug-Drug Interactions and Therapeutic Drug Monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and Others","volume":"40","author":"Protti","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration-Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges","volume":"41","author":"Hiemke","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/17425255.2021.1974400","article-title":"Therapeutic Drug Monitoring of Clozapine in Adults with Schizophrenia: A Review of Challenges and Strategies","volume":"17","author":"Molden","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00213-020-05715-5","article-title":"The Usefulness of Olanzapine Plasma Concentrations in Monitoring Treatment Efficacy and Metabolic Disturbances in First-Episode Psychosis","volume":"238","author":"Arnaiz","year":"2021","journal-title":"Psychopharmacology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/FTD.0000000000000358","article-title":"Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1","volume":"39","author":"Nagai","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20451253221113238","DOI":"10.1177\/20451253221113238","article-title":"Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan","volume":"12","author":"Tien","year":"2022","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s00213-022-06233-2","article-title":"Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: A Systematic Review and Metaanalysis","volume":"239","author":"Hart","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.euroneuro.2019.12.108","article-title":"Corrigendum to \u201cChanges in Psychopathology in Schizophrenia Patients Starting Treatment with New-Generation Antipsychotics: Therapeutic Drug Monitoring in a Naturalistic Treatment Setting\u201d","volume":"31","author":"Kaufmann","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00406-016-0736-z","article-title":"Clinical Response in a Risperidone-Medicated Naturalistic Sample: Patients\u2019 Characteristics and Dose-Dependent Pharmacokinetic Patterns","volume":"267","author":"Paulzen","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/acps.13264","article-title":"The Relationship between Plasma Clozapine Concentration and Clinical Outcome: A Cross-Sectional Study","volume":"143","author":"Yada","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40263-021-00847-4","article-title":"Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients","volume":"35","author":"Smith","year":"2021","journal-title":"CNS Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A Comprehensive Review of the Clinical Utility of and a Combined Analysis of the Clozapine\/Norclozapine Ratio in Therapeutic Drug Monitoring for Adult Patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102939","DOI":"10.1016\/j.ajp.2021.102939","article-title":"Pharmacometabolomics-Guided Clozapine Therapy in Treatment Resistant Schizophrenia: Preliminary Exploration of Future Too Near","volume":"67","author":"Grover","year":"2022","journal-title":"Asian J. Psychiatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"20451253211030844","DOI":"10.1177\/20451253211030844","article-title":"Possible Pharmacogenetic Factors in Clozapine Treatment Failure: A Case Report","volume":"11","author":"Whiskey","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3163502","DOI":"10.1155\/2019\/3163502","article-title":"Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia","volume":"2019","author":"Olmos","year":"2019","journal-title":"BioMed Res. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/FTD.0000000000000711","article-title":"Clozapine and Norclozapine Plasma Levels in Patients Switched between Different Liquid Formulations","volume":"42","author":"Oloyede","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.schres.2018.05.028","article-title":"Relationship between Antipsychotic Blood Levels and Treatment Failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study","volume":"201","author":"Melkote","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/acps.12825","article-title":"Antipsychotic Plasma Levels in the Assessment of Poor Treatment Response in Schizophrenia","volume":"137","author":"McCutcheon","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41537-020-0107-7","article-title":"Undetectable or Subtherapeutic Serum Levels of Antipsychotic Drugs Preceding Switch to Clozapine","volume":"6","author":"Smith","year":"2020","journal-title":"NPJ Schizophr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ejhpharm-2018-001605","article-title":"High-Dose Quetiapine and Therapeutic Monitoring","volume":"26","author":"Javelot","year":"2019","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17512433.2018.1549489","article-title":"A Systematic Review and Combined Analysis of Therapeutic Drug Monitoring Studies for Long-Acting Paliperidone","volume":"11","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00406-021-01257-9","article-title":"Clinical Response in Patients Treated with Once-Monthly Paliperidone Palmitate: Analysis of a Therapeutic Drug Monitoring (TDM) Database","volume":"271","author":"Schoretsanitis","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/17512433.2022.2020641","article-title":"Effects of Body Weight, Smoking Status, and Sex on Plasma Concentrations of Once-Monthly Paliperidone Palmitate","volume":"15","author":"Schoretsanitis","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2147\/NDT.S298050","article-title":"Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis","volume":"17","author":"Grundmann","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_39","first-page":"79","article-title":"Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotics as a Predictor of Relapse in Schizophrenia Spectrum Disorders: A One-Year Pilot Study","volume":"43","author":"Rotella","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"ref_40","first-page":"1163","article-title":"Clinical Pharmacokinetics of Atypical Antipsychotics: An Update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/cts.12720","article-title":"Relationship Between Plasma Concentra-tions and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania","volume":"13","author":"Periclou","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bdi.12455","article-title":"Lithiumeter: Version 2.0","volume":"18","author":"Malhi","year":"2016","journal-title":"Bipolar Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/a-1113-7862","article-title":"Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the Prophylaxis of Bipolar Disorder Type I with Manic Predominance","volume":"53","author":"Mauri","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"826138","DOI":"10.3389\/fpsyt.2022.826138","article-title":"Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications from a Systematic Review and Meta-Analysis with Focus on Moderating Factors","volume":"13","author":"Funk","year":"2022","journal-title":"Front. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40266-020-00784-9","article-title":"Use of Antidepressants in Older People during a 10-Year Period: An Observational Study on Prescribed Doses and Serum Levels","volume":"37","author":"Tveit","year":"2020","journal-title":"Drugs Aging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/YIC.0000000000000386","article-title":"Antidepressant efficacy is correlated with plasma levels: Mega-analysis and further evidence","volume":"37","author":"Cellini","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_47","first-page":"183","article-title":"Venlafaxine and O-Desmethylvenlafaxine Serum Levels Are Positively Associated with Antidepressant Response in Elder Depressed out-Patients","volume":"23","author":"Porcelli","year":"2021","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bcpt.12796","article-title":"Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships","volume":"121","author":"Hansen","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/FTD.0000000000000480","article-title":"Therapeutic Drug Monitoring of Second-Generation Antipsychotics for the Estimation of Early Drug Effect in First-Episode Psychosis: A Cross-Sectional Assessment","volume":"40","author":"Bustillo","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1192\/bjb.2021.36","article-title":"Routine Clozapine Assay Monitoring to Improve the Management of Treatment-Resistant Schizophrenia","volume":"46","author":"Kitchen","year":"2021","journal-title":"BJPsych Bull."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/j.euroneuro.2020.09.362","article-title":"Case Report: Therapeutic Drug Monitoring in a Female Schizophrenia Patient with Self-Induced Clozapine Intoxication Using Point-of-Care Testing","volume":"40","author":"Hart","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s40263-017-0469-1","article-title":"Correlation between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study","volume":"31","author":"Smith","year":"2017","journal-title":"CNS Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JCP.0000000000000926","article-title":"The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data from a Double-Blind Trial","volume":"38","author":"Diaz","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40262-020-00944-5","article-title":"Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation","volume":"60","author":"Schoretsanitis","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Skokou, M., Karavia, E.A., Drakou, Z., Konstantinopoulou, V., Kavakioti, C.A., Gourzis, P., Kavakioti, C., Gourzis, P., Kypreos, K.E., and Andreopoulou, O. (2022). Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review. Pharmaceuticals, 15.","DOI":"10.3390\/ph15070817"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41537-022-00211-5","article-title":"Association between olanzapine concentration and metabolic dysfunction in drug-naive and chronic patients: Similarities and differences","volume":"8","author":"Kang","year":"2022","journal-title":"Schizophr"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"930457","DOI":"10.3389\/fpsyt.2022.930457","article-title":"Relationship between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients with Schizophrenia","volume":"13","author":"An","year":"2022","journal-title":"Front. Psychiatry"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.schres.2017.07.022","article-title":"Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Metabolic Parameters in Patients with Schizophrenia","volume":"193","author":"Lu","year":"2018","journal-title":"Schizophr Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., and Scarselli, M. (2021). Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030238"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/JCP.0000000000001312","article-title":"Tolerability of High-Dose Venlafaxine after Switch from Escitalopram in Nonresponding Patients with Major Depressive Disorder","volume":"41","author":"Engelmann","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s40262-021-01044-8","article-title":"Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions","volume":"60","author":"Schoretsanitis","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0000000000001131","article-title":"Dopamine D2 Receptor Occupancy Estimated from Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results from the Randomized NeSSy Trial","volume":"39","author":"Scharpenberg","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with Antipsychotic Medication in Schizophrenia: Challenges and Management Strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Relat. Outcome Meas."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication Adherence in Schizophrenia: Factors Influencing Adherence and Consequences of Nonadherence, a Systematic Literature Review","volume":"3","author":"Higashi","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jad.2013.08.026","article-title":"Treatment Adherence in Bipolar I and Schizoaffective Disorder, Bipolar Type","volume":"151","author":"Murru","year":"2013","journal-title":"J. Affect. Disord."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Emsley, R., Chiliza, B., Asmal, L., and Harvey, B.H. (2013). The Nature of Relapse in Schizophrenia. BMC Psychiatry, 13.","DOI":"10.1186\/1471-244X-13-50"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/pcn.12809","article-title":"Non-Adherence to Psychotropic Medication Assessed by Plasma Level in Newly Admitted Psychiatric Patients: Prevalence before Acute Admission","volume":"73","author":"Geretsegger","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0044-101838","article-title":"What Does Antidepressant Drug Level Monitoring Reveal about Outpatient Treatment and Patient Adherence?","volume":"52","author":"Silhan","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/15622975.2020.1747112","article-title":"Therapeutic Drug Monitoring and Pharmacogenetics of Antipsychotics and Antidepressants in Real Life Settings: A 5-Year Single Centre Experience","volume":"22","author":"Baldelli","year":"2021","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/JCP.0000000000000697","article-title":"Accuracy of Clinician Assessments of Medication Status in the Emergency Setting: A Comparison of Clinician Assessment of Antipsychotic Usage and Plasma Level Determination","volume":"37","author":"Lopez","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"114214","DOI":"10.1016\/j.psychres.2021.114214","article-title":"Accuracy of Self-Reported Adherence and Therapeutic Drug Monitoring in a Psychiatric Emergency Ward","volume":"305","author":"Brasso","year":"2021","journal-title":"Psychiatry Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.euroneuro.2020.06.007","article-title":"Impact of Antipsychotic Polypharmacy on Nonadherence of Oral Antipsychotic Drugs\u2014A Study Based on Blood Sample Analyses from 24,239 Patients","volume":"37","author":"Smith","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"531763","DOI":"10.3389\/fnins.2020.531763","article-title":"Antipsychotic Treatment Failure: A Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis","volume":"14","author":"Morrens","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.schres.2020.11.025","article-title":"Rates of Complete Nonadherence among Atypical Antipsychotic Drugs: A Study Using Blood Samples from 13,217 Outpatients with Psychotic Disorders","volume":"228","author":"Smith","year":"2021","journal-title":"Schizophr Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(14)61278-2","article-title":"Bipolar Disorder, Affective Psychosis, and Schizophrenia in Pregnancy and the Post-Partum Period","volume":"384","author":"Jones","year":"2014","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"19cs13169","DOI":"10.4088\/JCP.19cs13169","article-title":"Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft F\u00fcr Neuropsychopharmakologie Und Pharmakopsychiatrie","volume":"81","author":"Schoretsanitis","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Leutritz, A.L., van Braam, L., Preis, K., Gehrmann, A., Scherf-Clavel, M., Fiedler, K., Unterecker, S., and Kittel-Schneider, S. (2022). Psychotropic medication in pregnancy and lactation and early development of exposed children. Br. J. Clin. Pharmacol.","DOI":"10.22541\/au.165212107.74134134\/v1"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2147\/DDDT.S327506","article-title":"Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level","volume":"15","author":"Huang","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e015738","DOI":"10.1136\/bmjopen-2016-015738","article-title":"Changes in Drug Disposition of Lithium during Pregnancy: A Retrospective Observational Study of Patient Data from Two Routine Therapeutic Drug Monitoring Services in Norway","volume":"7","author":"Westin","year":"2017","journal-title":"BMJ Open"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/jcph.2089","article-title":"Lithium Pharmacokinetics in the Perinatal Patient with Bipolar Disorder","volume":"62","author":"Clark","year":"2022","journal-title":"J. Clin. Pharm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/17425255.2020.1750598","article-title":"The Impact of Pregnancy on the Pharmacokinetics of Antidepressants: A Systematic Critical Review and Meta-Analysis","volume":"16","author":"Schoretsanitis","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00737-018-0905-3","article-title":"Antidepressants in Breast Milk; Comparative Analysis of Excretion Ratios","volume":"22","author":"Schoretsanitis","year":"2019","journal-title":"Arch. Womens Ment. Health"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00228-021-03122-z","article-title":"Sertraline Concentrations in Pregnant Women Are Steady and the Drug Transfer to Their Infants Is Low","volume":"77","author":"Heinonen","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cpt.770","article-title":"Treatment with Antipsychotics in Pregnancy: Changes in Drug Disposition","volume":"103","author":"Westin","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbr030","article-title":"Age of Onset of Schizophrenia: Perspectives from Structural Neuroimaging Studies","volume":"37","author":"Gogtay","year":"2011","journal-title":"Schizophr Bull."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bdi.13016","article-title":"Bipolar Disorder: Trimodal Age-at-Onset Distribution","volume":"23","author":"Bolton","year":"2021","journal-title":"Bipolar Disord."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ijnp\/pyz034","article-title":"Maintenance Pharmacological Treatment of Juvenile Bipolar Disorder: Review and Meta-Analyses","volume":"22","author":"Yee","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","article-title":"Efficacy, Acceptability, and Tolerability of Antipsychotics in Children and Adolescents with Schizophrenia: A Network Meta-Analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/0706743716659276","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly","volume":"61","author":"MacQueen","year":"2016","journal-title":"Can. J. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(16)30385-3","article-title":"Comparative Efficacy and Tolerability of Antidepressants for Major Depressive Disorder in Children and Adolescents: A Network Meta-Analysis","volume":"388","author":"Cipriani","year":"2016","journal-title":"Lancet"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"152301","DOI":"10.1016\/j.comppsych.2022.152301","article-title":"Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder","volume":"115","author":"Tini","year":"2022","journal-title":"Compr. Psychiatry"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/FTD.0000000000000685","article-title":"Dose-Related Concentrations of Neuroactive\/Psychoactive Drugs Expected in Blood of Children and Adolescents","volume":"42","author":"Fekete","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14740338.2020.1770224","article-title":"Psychotropic Drug Concentrations and Clinical Outcomes in Children and Adolescents: A Systematic Review","volume":"19","author":"Kloosterboer","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"749692","DOI":"10.3389\/fphar.2021.749692","article-title":"Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors","volume":"12","author":"Strawn","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/a-1302-8108","article-title":"Dose-Corrected Serum Concentrations and Metabolite to Parent Compound Ratios of Venlafaxine and Risperidone from Childhood to Old Age","volume":"54","author":"Fekete","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.9758\/cpn.2020.18.1.41","article-title":"Plasma Risperidone-Related Measures in Children and Adolescents with Oppositional Defiant\/Conduct Disorders","volume":"18","author":"Piacentino","year":"2020","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00702-020-02253-4","article-title":"Therapeutic Drug Monitoring of Children and Adolescents Treated with Aripiprazole: Observational Results from Routine Patient Care","volume":"127","author":"Egberts","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1024\/1422-4917\/a000637","article-title":"Serum Level Measurements Optimize Aripriprazole Treatment in Adolescent Patients","volume":"47","author":"Gehrmann","year":"2019","journal-title":"Z. Kinder. Jugendpsychiatr. Psychother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of Age and Gender on the Serum Levels of Clozapine, Olanzapine, Risperidone, and Quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/FTD.0000000000000585","article-title":"A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting","volume":"41","author":"Spigset","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/gps.4758","article-title":"Therapeutic D2\/3 Receptor Occupancies and Response with Low Amisulpride Blood Concentrations in Very Late-Onset Schizophrenia-like Psychosis (VLOSLP)","volume":"33","author":"Reeves","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00228-020-03002-y","article-title":"Impact of Age and CYP2D6 Genotype on Exposure of Zuclopenthixol in Patients Using Long-Acting Injectable versus Oral Formulation-an Observational Study Including 2044 Patients","volume":"77","author":"Tveito","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JCP.0000000000000961","article-title":"Age Impacts Olanzapine Exposure Differently during Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8288 Patients","volume":"38","author":"Tveito","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/FTD.0000000000000738","article-title":"A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors","volume":"42","author":"Deng","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JCP.0000000000001390","article-title":"Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-Desmethyl Olanzapine in Inpatients With Schizophrenia","volume":"41","author":"An","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00228-021-03114-z","article-title":"Impact of Age and Gender on Paliperidone Exposure in Patients after Administration of Long-Acting Injectable Formulations-an Observational Study Using Blood Samples from 1223 Patients","volume":"77","author":"Tveito","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/FTD.0000000000000540","article-title":"Clinically Relevant Effect of UGT1A4*3 on Lamotrigine Serum Concentration Is Restricted to Postmenopausal Women\u2014A Study Matching Therapeutic Drug Monitoring and Genotype Data From 534 Patients","volume":"40","author":"Smith","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-0044-102009","article-title":"QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients","volume":"52","author":"Hefner","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00702-022-02485-6","article-title":"Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone","volume":"129","author":"Taurines","year":"2022","journal-title":"J. Neural Transm."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0269881120985166","article-title":"Body Mass Index as a Determinant of Clozapine Plasma Concentrations: A Pharmacokinetic-Based Hypothesis","volume":"35","author":"Kuzin","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.clinthera.2017.04.005","article-title":"Population Pharmacokinetics of Valproic Acid in Patients with Mania: Implication for Individualized Dosing Regimens","volume":"39","author":"Methaneethorn","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/YIC.0000000000000234","article-title":"Sex and Body Weight Are Major Determinants of Venlafaxine Pharmacokinetics","volume":"33","author":"Schoretsanitis","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/FTD.0000000000000812","article-title":"Impact of Body Mass Index on Serum Concentrations of Antidepressants and Antipsychotics","volume":"43","author":"Warrings","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1248\/bpb.b22-00025","article-title":"New Insight Concerning Therapeutic Drug Monitoring-The Importance of the Concept of Psychonephrology","volume":"45","author":"Hashimoto","year":"2022","journal-title":"Biol. Pharm. Bull."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Moschny, N., Hefner, G., Grohmann, R., Eckermann, G., Maier, H.B., Seifert, J., Heck, J., Francis, F., Bleich, S., and Toto, S. (2021). Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060514"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/YIC.0000000000000366","article-title":"Infection Is Associated with Elevated Serum Concentrations of Antipsychotic Drugs","volume":"36","author":"Zhang","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/a-0869-8053","article-title":"Pathological Concentration of C-Reactive Protein Is Correlated to Increased Concentrations of Quetiapine, but Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting","volume":"53","author":"Weidner","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/JCP.0000000000000873","article-title":"Systemic Inflammation Complicates the Interpretation of Therapeutic Drug Monitoring of Risperidone","volume":"38","author":"Helland","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/bcp.13994","article-title":"Escitalopram Population Pharmacokinetics in People Living with Human Immunodeficiency Virus and in the Psychiatric Population: Drug-Drug Interactions and Probability of Target Attainment","volume":"85","author":"Courlet","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00228-021-03182-1","article-title":"Serum Concentrations of Antidepressants, Antipsychotics, and Antiepileptics over the Bariatric Surgery Procedure","volume":"77","author":"Wallerstedt","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0897190020905467","article-title":"Roux-En-Y Gastric Bypass and Antipsychotic Therapeutic Drug Monitoring: Two Cases","volume":"34","author":"McGrane","year":"2021","journal-title":"J. Pharm. Pract."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/acschemneuro.7b00375","article-title":"Medication Exposure in Highly Adherent Psychiatry Patients","volume":"9","author":"Sutherland","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/2045125316672573","article-title":"Variation in Dose and Plasma Level of Lamotrigine in Patients Discharged from a Mental Health Trust","volume":"7","author":"Dzahini","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/bcp.13255","article-title":"Cytochrome P450-Mediated Interaction between Perazine and Risperidone: Implications for Antipsychotic Polypharmacy","volume":"83","author":"Paulzen","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pnpbp.2017.03.002","article-title":"Pharmacokinetic Considerations in Antipsychotic Augmentation Strategies: How to Combine Risperidone with Low-Potency Antipsychotics","volume":"76","author":"Paulzen","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e100423","DOI":"10.1136\/gpsych-2020-100423","article-title":"Effects of the Combination of Second-Generation Antipsychotics on Serum Concentrations of Aripiprazole and Dehydroaripiprazole in Chinese Patients with Schizophrenia","volume":"34","author":"Jiang","year":"2021","journal-title":"Gen. Psychiatr."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JCP.0000000000000877","article-title":"Comedication of Valproic Acid Is Associated with Increased Metabolism of Clozapine","volume":"38","author":"Hommers","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/JCP.0000000000001507","article-title":"Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients with Schizophrenia","volume":"42","author":"Smith","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1111\/bcp.15223","article-title":"The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia","volume":"88","author":"Gaebler","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bcp.14471","article-title":"Metamizole but Not Ibuprofen Reduces the Plasma Concentration of Sertraline: Implications for the Concurrent Treatment of Pain and Depression\/Anxiety Disorders","volume":"87","author":"Gaebler","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pnpbp.2018.04.014","article-title":"Reduced Clearance of Venlafaxine in a Combined Treatment with Quetiapine","volume":"85","author":"Paulzen","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40262-017-0591-8","article-title":"Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine","volume":"57","author":"Kuzin","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1037\/pha0000334","article-title":"Clinical Collaborators of the GnG-PK\/PD-AD Study Pharmacogenetics and Therapeutic Drug Monitoring of Fluoxetine in a Real-World Setting: A PK\/PD Analysis of the Influence of (Non-)Genetic Factors","volume":"28","author":"Alves","year":"2020","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.13421","article-title":"Pharmacokinetic Interactions between Clozapine and Sertraline in Smokers and Non-Smokers","volume":"127","author":"Kuzin","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/a-1021-8827","article-title":"The Effects of Co-Prescription of Pantoprazole on the Clozapine Metabolism","volume":"53","author":"Kuzin","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/acps.12380","article-title":"Current Smoking Is Associated with Worse Cognitive and Adaptive Functioning in Serious Mental Illness","volume":"131","author":"Depp","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/wps.20773","article-title":"A Meta-Review of \u201cLifestyle Psychiatry\u201d: The Role of Exercise, Smoking, Diet and Sleep in the Prevention and Treatment of Mental Disorders","volume":"19","author":"Firth","year":"2020","journal-title":"World Psychiatry"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.psychres.2018.12.064","article-title":"Cognitive Functions in Smoking and Non-Smoking Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Comparative Studies","volume":"272","author":"Wang","year":"2019","journal-title":"Psychiatry Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-publhealth-031816-044618","article-title":"Smoking, Mental Illness, and Public Health","volume":"38","author":"Prochaska","year":"2017","journal-title":"Annu. Rev. Public Health"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"17m12086","DOI":"10.4088\/JCP.17m12086","article-title":"Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism","volume":"79","author":"Augustin","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/a-1221-5293","article-title":"Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-Analysis of a Naturalistic Therapeutic Drug Monitoring Sample","volume":"54","author":"Schoretsanitis","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.schres.2019.05.033","article-title":"Effect of Fluvoxamine Augmentation and Smoking on Clozapine Serum Concentrations","volume":"210","author":"Augustin","year":"2019","journal-title":"Schizophr Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/YIC.0000000000000250","article-title":"Analysis of Smoking Behavior on the Pharmacokinetics of Antidepressants and Antipsychotics: Evidence for the Role of Alternative Pathways Apart from CYP1A2","volume":"34","author":"Samanski","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Hart, X.M., Heesen, S., Schmitz, C.N., D\u00f6rfler, S., Wedekind, D., Gr\u00fcnder, G., Hiemke, C., and Havemann-Reinecke, U. (2022). Concentrations of escitalopram in blood of patients treated in a naturalistic setting: Focus on patients with alcohol and benzodiazepine use disorder. Eur. Arch. Psychiatry Clin. Neurosci., 1\u20139.","DOI":"10.1007\/s00406-022-01491-9"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","article-title":"Effect of CYP2D6 Genotype on Exposure and Efficacy of Risperidone and Aripiprazole: A Retrospective, Cohort Study","volume":"6","author":"Jukic","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/bcp.14626","article-title":"Impact of CYP2D6 on Serum Concentrations of Flupentixol, Haloperidol, Perphenazine and Zuclopenthixol","volume":"87","author":"Waade","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/cpt.2246","article-title":"Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated with Three Different CYP2D6 Substrates","volume":"110","author":"Smith","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/FTD.0000000000000695","article-title":"Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects","volume":"42","author":"Miroshnichenko","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jmoldx.2016.01.003","article-title":"Preemptive pharmacogenomic testing for precision medicine: A comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade","volume":"18","author":"Ji","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s40262-021-01041-x","article-title":"Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach","volume":"60","author":"Kneller","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41398-020-01061-4","article-title":"Correction: Identification of a Novel Polymorphism Associated with Reduced Clozapine Concentration in Schizophrenia Patients-a Genome-Wide Association Study Adjusting for Smoking Habits","volume":"10","author":"Smith","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2217\/pgs-2019-0074","article-title":"Implementation of Pharmacogenetics in a Clozapine Treatment Resistant Patient: A Case Report","volume":"20","author":"Cirujeda","year":"2019","journal-title":"Pharmacogenomics"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_154","first-page":"113","article-title":"The interplay between pharmacogenetics, concomitant drugs and blood levels of amitriptyline and its main metabolites","volume":"19","author":"Casha","year":"2021","journal-title":"Pers. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/JCP.0000000000001174","article-title":"The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort","volume":"40","author":"Kringen","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/bcp.13788","article-title":"Significantly Lower CYP2D6 Metabolism Measured as the O\/N-Desmethylvenlafaxine Metabolic Ratio in Carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: A Study on Therapeutic Drug Monitoring Data from 1003 Genotyped Scandinavian Patients","volume":"85","author":"Haslemo","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1055\/a-1872-0613","article-title":"Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response","volume":"55","author":"Weber","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"ref_158","first-page":"8","article-title":"Influence of CYP2C19*17 Genetic Polymorphism on the Steady-State Concentration of Escitalopram in Patients with Recurrent Depressive Disorder","volume":"52","author":"Zastrozhin","year":"2022","journal-title":"Psychopharmacol. Bull."},{"key":"ref_159","first-page":"840","article-title":"Subtherapeutic Bupropion and Hydroxybupropion Serum Concentrations in a Patient with CYP2C19*1\/*17 Genotype Suggesting a Rapid Metabolizer Status","volume":"20","author":"Gaebler","year":"2020","journal-title":"Pharm. J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0000000000000577","article-title":"Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy","volume":"41","author":"Suzuki","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"144513","DOI":"10.1016\/j.gene.2020.144513","article-title":"Effects of Plasma Concentration of Micro-RNA Mir-27b and CYP3A4*22 on Equilibrium Concentration of Alprazolam in Patients with Anxiety Disorders Comorbid with Alcohol Use Disorder","volume":"739","author":"Zastrozhin","year":"2020","journal-title":"Gene"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s40265-021-01618-7","article-title":"Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring","volume":"81","author":"Zijp","year":"2021","journal-title":"Drugs"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.euroneuro.2017.01.009","article-title":"Dried Blood Spot Sampling in Psychiatry: Perspectives for Improving Therapeutic Drug Monitoring","volume":"27","author":"Martial","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e1211","DOI":"10.4088\/JCP.16m11164","article-title":"Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine","volume":"78","author":"Geers","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"113384","DOI":"10.1016\/j.jpba.2020.113384","article-title":"Whole Blood and Oral Fluid Microsampling for the Monitoring of Patients under Treatment with Antidepressant Drugs","volume":"188","author":"Marasca","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1039\/D0AN01039A","article-title":"Assessment of Capillary Volumetric Blood Microsampling for the Analysis of Central Nervous System Drugs and Metabolites","volume":"145","author":"Protti","year":"2020","journal-title":"Analyst"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/FTD.0000000000000502","article-title":"Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Antipsychotics: Drawbacks of Its Clinical Application","volume":"40","author":"Kloosterboer","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"113102","DOI":"10.1016\/j.jpba.2020.113102","article-title":"Opportunities and Obstacles for Microsampling Techniques in Bioanalysis: Special Focus on DBS and VAMS","volume":"182","author":"Londhe","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"794609","DOI":"10.3389\/fpsyt.2022.794609","article-title":"Dried volumetric microsampling approaches for the therapeutic drug monitoring of psychiatric patients undergoing clozapine treatment","volume":"13","author":"Marasca","year":"2022","journal-title":"Front. Psychiatry"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4155\/bio-2020-0136","article-title":"Validation and Clinical Application of a Volumetric Absorptive Microsampling Method for 14 Psychiatric Drugs","volume":"12","author":"Stern","year":"2020","journal-title":"Bioanalysis"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4155\/bio-2020-0179","article-title":"Analysis of 14 Drugs in Dried Blood Mi-crosamples in a Single Workflow Using Whole Blood and Serum Calibrators","volume":"12","author":"Vincze","year":"2020","journal-title":"Bioanalysis"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Dziurkowska, E., and Weso\u0142owski, M. (2020). Effects of Age, Drug Dose, and Sampling Time on Salivary Levels of Olanzapine, Quetiapine, and Their Metabolites. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103288"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bdi.13128","article-title":"Saliva Testing as a Means to Monitor Therapeutic Lithium Levels in Patients with Psychiatric Disorders: Identification of Clinical and Environmental Covariates, and Their Incorporation into a Prediction Model","volume":"23","author":"Parkin","year":"2021","journal-title":"Bipolar Disord."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/FTD.0000000000000508","article-title":"Serum and Saliva Concentrations of Venlafaxine, O-Desmethylvenlafaxine, Quetiapine, and Citalopram in Psychiatric Patients","volume":"40","author":"Ebert","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/FTD.0000000000000831","article-title":"Relationship between Amphetamine Concentrations in Saliva and Serum in Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder","volume":"43","author":"Wohkittel","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/FTD.0000000000000493","article-title":"Potential of Oral Fluid as a Clinical Specimen for Compliance Monitoring of Psychopharmacotherapy","volume":"40","author":"Neumann","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1109\/JSEN.2020.3009538","article-title":"A Wearable Electrochemical Sensing System for Non-Invasive Monitoring of Lithium Drug in Bipolar Disorder","volume":"21","author":"Criscuolo","year":"2021","journal-title":"IEEE Sens. J."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"111897","DOI":"10.1016\/j.bios.2019.111897","article-title":"Textile-Based Non-Invasive Lithium Drug Monitoring: A Proof-of-Concept Study for Wearable Sensing","volume":"150","author":"Sweilam","year":"2020","journal-title":"Biosens. Bioelectron."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2020.05.025","article-title":"Bioassay: A Novel Approach in Antipsychotic Pharmacology","volume":"509","author":"Mobed","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.snb.2018.10.012","article-title":"A Simple Smartphone-Based Thermochemiluminescent Immunosensor for Valproic Acid Detection Using 1,2-Dioxetane Analogue-Doped Nanoparticles as a Label","volume":"279","author":"Roda","year":"2019","journal-title":"Sens. Actuators B Chem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"620936","DOI":"10.3389\/fendo.2021.620936","article-title":"Psychotropic Drugs Levels in Seminal Fluid: A New Therapeutic Drug Monitoring Analysis?","volume":"12","author":"Mazzilli","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clinms.2017.11.001","article-title":"Identification of Metabolites of Brexpiprazole in Human Urine for Use in Monitoring Patient Compliance","volume":"6","author":"Enders","year":"2017","journal-title":"Clin. Mass. Spectrom."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders","volume":"167","author":"Insel","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cJust the Facts\u201d 4. Clinical Features and Conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bdi.13105","article-title":"Consensus on Nomenclature for Clinical Staging Models in Bipolar Disorder: A Narrative Review from the International Society for Bipolar Disorders (ISBD) Staging Task Force","volume":"23","author":"Kupka","year":"2021","journal-title":"Bipolar Disord."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41380-018-0055-z","article-title":"A Decade in Psychiatric GWAS Research","volume":"24","author":"Horwitz","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e1155","DOI":"10.1038\/tp.2017.115","article-title":"Genome-Wide Association Study of Borderline Personality Disorder Reveals Genetic Overlap with Bipolar Disorder, Major Depression and Schizophrenia","volume":"7","author":"Witt","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/appi.ajp.2019.19050521","article-title":"A Reckoning and Research Agenda for Neuroimaging in Psychiatry","volume":"176","author":"Etkin","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajmg.b.32208","article-title":"In Search of Biomarkers in Psychiatry: EEG-Based Measures of Brain Function","volume":"165B","author":"McLoughlin","year":"2014","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Kam, H., and Jeong, H. (2020). Pharmacogenomic Biomarkers and Their Applications in Psychiatry. Genes, 11.","DOI":"10.3390\/genes11121445"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"180031","DOI":"10.1098\/rsob.180031","article-title":"Prediction of Response to Drug Therapy in Psychiatric Disorders","volume":"8","author":"Stern","year":"2018","journal-title":"Open Biol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"211","DOI":"10.9758\/cpn.2022.20.2.211","article-title":"Potential Candidates for Biomarkers in Bipolar Disorder: A Proteomic Approach through Systems Biology","volume":"20","author":"Ziani","year":"2022","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1038\/tp.2016.10","article-title":"Antipsychotic Pharmacogenomics in First Episode Psychosis: A Role for Glutamate Genes","volume":"6","author":"Stevenson","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-981-32-9721-0_10","article-title":"Biomarker-Guided Tailored Therapy","volume":"1192","author":"Lydiard","year":"2019","journal-title":"Front. Psychiatry"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/12\/2674\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:30:58Z","timestamp":1760146258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/12\/2674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":194,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["pharmaceutics14122674"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14122674","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}